Supernus Pharmaceuticals ( SUPN ) Surpasses Q2 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of +93.62% and +7.34%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Sage ( SAGE ) Q2 Revenue Jumps 264%
Sage Therapeutics ( NASDAQ:SAGE ) , a biopharmaceutical company focused on developing medicines for brain health disorders, released its second quarter 2025 results on July 30, 2025. The most important news from the quarter was the significant revenue beat, as sales reached $31.7 million ( GAAP ) ...
Biogen's Q2 Earnings & Sales Beat, 2025 Outlook Raised, Stock Up
BIIB posts Q2 earnings and sales beat, lifts 2025 outlook on new drug growth and displays resilient MS performance.
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
ROCKVILLE, Md., July 31, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. SUPN ( "Supernus" ) today announced that it has successfully completed its previously announced acquisition of Sage Therapeutics, Inc. SAGE ( "Sage" ) .
Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics
Acquisition strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® ( zuranolone ) , and a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth and further diversifying revenue base Acquisition ...
Biogen Gears Up to Report Q2 Earnings: Here's What to Expect
Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
ROCKVILLE, Md., July 28, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc., a Delaware corporation SUPN ( "Supernus", and the "Company" ) , today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ( "HSR Act" ) , with ...
Supernus Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Sage Therapeutics, Inc. Tender Offer
ROCKVILLE, Md., July 28, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc., a Delaware corporation ( NASDAQ: SUPN ) ( "Supernus", and the "Company" ) , today announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ( "HSR Act" ...
Supernus Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 5, 2025
ROCKVILLE, Md., July 22, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, today announced that the Company expects to report ...
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Sage Therapeutics, Inc. ( NASDAQ: SAGE )
NEW YORK, July 01, 2025 ( GLOBE NEWSWIRE ) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. ( Nasdaq - VERV ) , Sage Therapeutics, Inc. ( Nasdaq - SAGE ) , Cantaloupe, Inc. ( Nasdaq - CTLP ) , Volato Group, Inc. ( NYSE American - SOAR )
BALA CYNWYD, Pa., June 27, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GNTY, CHTR, SAGE, TASK on Behalf of Shareholders - Charter Communications ( NASDAQ:CHTR ) , Guaranty Bancshares ( NYSE:GNTY )
NEW YORK, June 25, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Guaranty Bancshares, Inc.
SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal
SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.
These Analysts Revise Their Forecasts On Sage Therapeutics Following Acquisition News - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. ( Nasdaq - VERV ) , Sage Therapeutics, Inc. ( Nasdaq - SAGE ) , Cantaloupe, Inc. ( Nasdaq - CTLP ) , Volato Group, Inc. ( NYSE American - SOAR )
BALA CYNWYD, Pa., June 17, 2025 ( GLOBE NEWSWIRE ) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ( [email protected] ) or Marc Ackerman ( [email protected] ) at 855-576-4847.
Sage Therapeutics ( SAGE ) Soars 35.4%: Is Further Upside Left in the Stock?
Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Top 3 Health Care Stocks That Are Ticking Portfolio Bombs - Sage Therapeutics ( NASDAQ:SAGE ) , Regencell Bioscience ( NASDAQ:RGC )
As of June 17, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June - Robin Energy ( NASDAQ:RBNE ) , LZ Technology Hldgs ( NASDAQ:LZMH )
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 1% on Monday. The Dow traded up 0.80% to 42,536.72 while the NASDAQ climbed 1.51% to 19,699.21. The S&P 500 also rose, gaining, 0.97% to 6,034.20. Financial shares jumped by 1.7% on Monday.
Sage Therapeutics, Roku, EchoStar And Other Big Stocks Moving Higher On Monday - Advanced Micro Devices ( NASDAQ:AMD ) , AIRO Group Holdings ( NASDAQ:AIRO )
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Monday. Shares of Sage Therapeutics, Inc. SAGE rose sharply during Monday's session after Supernus Pharmaceuticals agreed to acquire the company.
Supernus Pharma Acquires Maker Of Postpartum Depression Drug Zurzuvae In $795 Million Deal - Sage Therapeutics ( NASDAQ:SAGE ) , Biogen ( NASDAQ:BIIB )
Supernus Pharmaceuticals, Inc. SUPN on Monday agreed to acquire Sage Therapeutics, Inc. SAGE for $12.00 per share in cash, or an aggregate of up to approximately $795 million.
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio - Supernus Pharmaceuticals ( NASDAQ:SUPN ) , Sage Therapeutics ( NASDAQ:SAGE )
Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base. Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® ( zuranolone ) , and a novel CNS discovery platform.
Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
ROCKVILLE, Md. and CAMBRIDGE, Mass., June 16, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) and Sage Therapeutics, Inc. ( Nasdaq: SAGE ) , today announced a definitive agreement for Supernus to acquire Sage through a tender offer for $8.50 per share in cash ( or an ...
Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals - Supernus Pharmaceuticals ( NASDAQ:SUPN )
ROCKVILLE, Md., May 29, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer.
Supernus Announces Paragraph IV ANDA Filings for Qelbree® - Supernus Pharmaceuticals ( NASDAQ:SUPN )
ROCKVILLE, Md., May 28, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc.
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference - Supernus Pharmaceuticals ( NASDAQ:SUPN )
ROCKVILLE, Md., May 28, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that Jack A.
Supernus to Participate in the 2025 Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 28, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that Jack A.
Supernus Announces Paragraph IV ANDA Filings for Qelbree®
ROCKVILLE, Md., May 28, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, today announced that the Company received Paragraph IV ...
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals ( SUPN ) Stock?
Investors need to pay close attention to Supernus Pharmaceuticals (SUPN) stock based on the movements in the options market lately ...
Supernus Pharmaceuticals ( SUPN ) Q1 Earnings and Revenues Surpass Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 10.53% and 2.91%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
What Makes Supernus ( SUPN ) a New Buy Stock
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025
ROCKVILLE, Md., April 23, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, today announced that the Company expects to report ...
Down -20.07% in 4 Weeks, Here's Why Supernus ( SUPN ) Looks Ripe for a Turnaround
Supernus (SUPN) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Supernus to Participate in Two Upcoming Investor Conferences - Supernus Pharmaceuticals ( NASDAQ:SUPN )
ROCKVILLE, Md., March 04, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc.
Supernus to Participate in Two Upcoming Investor Conferences
ROCKVILLE, Md., March 04, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that Jack Khattar, President and CEO ...
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference - Supernus Pharmaceuticals ( NASDAQ:SUPN )
ROCKVILLE, Md., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. SUPN, a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that Jack A.
Supernus to Participate in the TD Cowen 45th Annual Health Care Conference
ROCKVILLE, Md., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that Jack A.
Supernus Pharmaceuticals ( SUPN ) Beats Q4 Earnings and Revenue Estimates
Supernus (SUPN) delivered earnings and revenue surprises of 44.23% and 12.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Personalis ( PSNL ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Personalis (PSNL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BREAKING: Supernus Pharmaceuticals, Inc. Shares Down 14%; Investors Should Contact Block & Leviton to Find Out How They Might Recover Money Through The Firm's Investigation - Supernus Pharmaceuticals ( NASDAQ:SUPN )
BOSTON, Feb. 19, 2025 ( GLOBE NEWSWIRE ) -- Block & Leviton is investigating Supernus Pharmaceuticals, Inc. SUPN for potential securities law violations. Investors who have lost money in their Supernus Pharmaceuticals, Inc. investment should contact the firm to learn more about how they might ...
This Workday Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - CervoMed ( NASDAQ:CRVO ) , Qiagen ( NYSE:QGEN )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Baird analyst Catherine Schulte downgraded the rating for Qiagen N.V.
Supernus Pharmaceuticals Stock Falls On Disappointing Data From Treatment-Resistant Depression Trial - Supernus Pharmaceuticals ( NASDAQ:SUPN )
Supernus' SPN-820 failed to show significant improvement in depression severity in its Phase 2b study, with no difference from placebo. The safety profile of SPN-820 remained consistent with previous trials, and Supernus will evaluate the next steps.
Gentherm Posts Downbeat Results, Joins Celanese, Bumble And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Celanese ( NYSE:CE ) , Bumble ( NASDAQ:BMBL )
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Wednesday. Shares of Gentherm Incorporated THRM fell sharply in today's pre-market trading following weak quarterly results. Gentherm shares dipped 17% to $30.00 in the pre-market trading session.
Why Global Blue Group Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket - Aptose Biosciences ( NASDAQ:APTO ) , Aditxt ( NASDAQ:ADTX )
Shares of Global Blue Group Holding AG GB rose sharply during Wednesday's pre-market trading session after the company announced it will be acquired by Shift4 for $7.50 per share. Global Blue Group shares jumped 18.3% to $7.37 in the pre-market trading session.
Supernus Announces Topline Results from Phase 2b Study in Adults with Treatment Resistant Depression
ROCKVILLE, Md., Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that the Phase 2b study of SPN-820 in ...
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results - Supernus Pharmaceuticals ( NASDAQ:SUPN )
ROCKVILLE, Md., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results
ROCKVILLE, Md., Feb. 11, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, today announced that the Company expects to report ...
Supernus ( SUPN ) Moves to Strong Buy: Rationale Behind the Upgrade
Supernus (SUPN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Supernus Announces FDA Approval of ONAPGO™ ( apomorphine hydrochloride ) for Parkinson's Disease
ROCKVILLE, Md., Feb. 04, 2025 ( GLOBE NEWSWIRE ) -- Supernus Pharmaceuticals, Inc. ( Nasdaq: SUPN ) , a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system ( CNS ) diseases, announced today that the U.S.
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy -- NEW YORK and VANCOUVER, British Columbia, Jan. 07, 2025 ( GLOBE NEWSWIRE ) -- Bright Minds Biosciences, Inc. ( "Bright Minds," "BMB" or the "Company" ) ( NASDAQ: DRUG ) , a pioneering company focused on ...
Bright Minds Biosciences Appoints Pharmaceutical Leader, Stephen Collins, M.D., Ph.D., as Chief Medical Officer - Bright Minds Biosciences ( NASDAQ:DRUG )
-- Dr. Collins brings extensive drug development and clinical expertise in epilepsy --
